Orion has entered into numerous license agreements and collaborations with academic institutions and universities worldwide. These collaborations have allowed Orion to strengthen its biomarker discovery and product pipeline. A summary of each commercial agreement is shown here:
To maximize the value of the methylation detection and discovery patent estate, Orion is exploring opportunities to further capitalize on the power of the MethylScope and MethylScreen estates in the research use market. Discussions regarding potential acquisitions and/or licenses to the estates for research use only are currently underway with various entities.